News
NTLA
12.16
-1.38%
-0.17
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 2h ago
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Seeking Alpha · 11h ago
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha · 1d ago
Weekly Report: what happened at NTLA last week (0914-0918)?
Weekly Report · 3d ago
Cathie Wood's Ark weekly recap: buys Meta, gene-editing stocks while cutting Alphabet
Seeking Alpha · 09/14 11:10
Weekly Report: what happened at NTLA last week (0907-0911)?
Weekly Report · 09/14 09:49
Cathie Wood Sells $28.6M of Google Stock and Buys $26.4 M of Meta Shares. What Else Is She Buying? September 10
TipRanks · 09/10 11:30
Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today
TipRanks · 09/10 00:10
Intellia Therapeutics Price Target Maintained With a $30.00/Share by Citizens
Dow Jones · 09/09 13:14
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Benzinga · 09/09 13:04
Intellia Therapeutics Price Target Raised to $13.00/Share From $12.00 by Wedbush
Dow Jones · 09/09 12:28
Intellia Therapeutics Is Maintained at Neutral by Wedbush
Dow Jones · 09/09 12:28
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13
Benzinga · 09/09 12:19
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)
TipRanks · 09/09 11:10
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
Benzinga · 09/09 10:59
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 09/09 10:43
Intellia’s Lonvo-z Gains FDA Priority Review for HAE
TipRanks · 09/08 20:35
3 Promising Genomics Stocks in the Spotlight in 2026
NASDAQ · 09/08 16:46
Intellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027
NASDAQ · 09/08 14:54
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Seeking Alpha · 09/08 12:55
More
Webull provides a variety of real-time NTLA stock news. You can receive the latest news about Intellia Therape through multiple platforms. This information may help you make smarter investment decisions.
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.